The Food and Drug Administration today authorized Innovative Health Solutions Inc. to market an electrical nerve stimulator device to relieve opioid withdrawal symptoms when placed behind the patient’s ear. Previously approved for use in acupuncture, the NSS-2 Bridge device reduced symptoms for patients undergoing opioid withdrawal during a clinical study by at least 31% within 30 minutes, based on the clinical opiate withdrawal scale. Sixty-four of the 73 patients in the study transitioned to medication assisted therapy after five days using the device. “The FDA is committed to supporting the development of novel treatments, both drugs and devices, that can be used to address opioid dependence or addiction, as well as new, non-addictive treatments for pain that can serve as alternatives to opioids,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…
Headline
In a study of Blue Cross and Blue Shield enrollees reported last week in the New England Journal of Medicine, initial opioid prescriptions declined 54 percent…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and…
Headline
As more female physicians enter the workforce and face challenges that can lead to burnout, the AHA has joined with five medical organizations to bring…
Headline
Eligible organizations can apply through May 6 for up to $1 million each for a three-year period to expand opioid and other substance use disorder services in…
Insights and Analysis
Also in this roundup of nursing news: a nurse perseveres through extreme snow to tend to a home-bound patient, and executive moves in the field.